热门资讯> 正文
Ironwood因与不良相关的挑战而在杰富瑞降级
2025-04-16 00:10
- Ironwood Pharmaceuticals (NASDAQ:IRWD) has been downgraded to Hold from Buy at Jefferies after the company announced pressures related to its lead asset, apraglutide.
- The company announced Monday that it has decided to evaluate strategic alternatives after the FDA required an additional Phase 3 trial to secure approval for its apraglutide.
- The downgrade by Jefferies reflects increased uncertainty around the drug’s development timeline and approval prospects, with analysts saying that while they previously viewed apraglutide’s clinical profile as a strength, the need for another pivotal study introduces a delay in potential approval, now expected no earlier than 2029, and adds regulatory and financial uncertainty.
- Jefferies has lowered its PT to $0.70 from $8 per share.
More on Ironwood Pharmaceuticals
- Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth
- Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call Transcript
- Ironwood looks for strategic options after regulatory hurdle for lead drug
- Ironwood Pharmaceuticals announces Nasdaq non-compliance notice
- Seeking Alpha’s Quant Rating on Ironwood Pharmaceuticals
推荐文章
华盛早报丨重大突破！三大加密货币法案众议院闯关成功；美联储，降息大消息
黄仁勋年内三度访华！H20重返中国市场，释放了什么信号？
美股机会日报 | 6月零售数据高于市场预期；台积电绩后涨超3%
美股“七巨头”迎特朗普关税后首次大考！Q2能否交出亮眼成绩单，继续引领美股上涨？
华盛早报丨TACO交易再现！特朗普闪电改口“解雇鲍威尔”；美国众议院加密货币立法进程受阻
财报前瞻 | 特斯拉Q2营收料下滑10%！股价销量双杀下，马斯克能否逆转局势？
美股机会日报 | 低于市场预期！美国6月PPI同比增长2.3%；特斯拉官宣Model Y L
华盛早报丨事关中美关税！美财长最新放风；“加密周”突发！多项加密货币法案遭众议院否决
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
